FI896029A0 - Cysteinproteinas-inhibitor. - Google Patents

Cysteinproteinas-inhibitor.

Info

Publication number
FI896029A0
FI896029A0 FI896029A FI896029A FI896029A0 FI 896029 A0 FI896029 A0 FI 896029A0 FI 896029 A FI896029 A FI 896029A FI 896029 A FI896029 A FI 896029A FI 896029 A0 FI896029 A0 FI 896029A0
Authority
FI
Finland
Prior art keywords
cysteinproteinas
inhibitor
Prior art date
Application number
FI896029A
Other languages
English (en)
Finnish (fi)
Inventor
Anders Grubb
Magnus Abrahamson
Jerzy Trojnar
Original Assignee
Anders Grubb
Magnus Abrahamson
Jerzy Trojnar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anders Grubb, Magnus Abrahamson, Jerzy Trojnar filed Critical Anders Grubb
Publication of FI896029A0 publication Critical patent/FI896029A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI896029A 1987-06-18 1989-12-15 Cysteinproteinas-inhibitor. FI896029A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8702550A SE8702550D0 (sv) 1987-06-18 1987-06-18 Cysteinproteashemmare
PCT/SE1988/000334 WO1988010266A1 (fr) 1987-06-18 1988-06-17 Inhibiteur de proteinase de cysteine

Publications (1)

Publication Number Publication Date
FI896029A0 true FI896029A0 (fi) 1989-12-15

Family

ID=20368906

Family Applications (1)

Application Number Title Priority Date Filing Date
FI896029A FI896029A0 (fi) 1987-06-18 1989-12-15 Cysteinproteinas-inhibitor.

Country Status (7)

Country Link
US (1) US5037957A (fr)
EP (1) EP0418233A1 (fr)
JP (1) JPH02503917A (fr)
AU (1) AU604944B2 (fr)
FI (1) FI896029A0 (fr)
SE (1) SE8702550D0 (fr)
WO (1) WO1988010266A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189144A (en) * 1989-04-28 1993-02-23 Takara Shuzo Co., Ltd. Human calpastatin-like polypeptide
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
US5472945A (en) * 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
ES2202359T3 (es) * 1994-04-19 2004-04-01 Kanebo Ltd. Producto preventivo para enfermedades circulatorias.
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5905076A (en) * 1996-04-10 1999-05-18 National Research Council Of Canada 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors
US6803357B1 (en) 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
US6514941B1 (en) 1999-12-10 2003-02-04 Campina Melkunie B.V. Method of preparing a casein hydrolysate enriched in anti-hypertensive peptides
WO2003045228A2 (fr) 2001-11-26 2003-06-05 Trustees Of Tufts College Techniques de traitement de maladies auto-immunes et reactifs associes
EA006860B1 (ru) * 2002-01-29 2006-04-28 Уайт Композиции и способы модулирования гемиканалов коннексина
WO2004043374A2 (fr) 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome
EP1948223A4 (fr) 2005-10-07 2009-10-21 Biopharmica Ltd Agent de contrôle de sumoylation et applications
US20090258827A1 (en) 2006-04-07 2009-10-15 Biopharmica Ltd. Transcription Factor Modulator
CN107141410B (zh) 2010-05-25 2022-12-09 辛德弗雷克斯公司 聚合物缀合的MetAP2抑制剂及其应用的治疗方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
AU2014250983B2 (en) * 2013-04-10 2019-04-11 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
WO2017100553A1 (fr) 2015-12-10 2017-06-15 Syndevrx, Inc. Dérivés de fumagillol et leurs polymorphes
IL260369B2 (en) 2016-01-06 2024-03-01 Lonza Ag Inhibition of protein breakdown for improved production
CN108697807B (zh) 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
CN112188892A (zh) 2018-03-20 2021-01-05 阿布拉科斯生物科学有限公司 通过mTOR抑制剂和白蛋白的纳米颗粒的施用治疗中枢神经系统障碍的方法
AU2019366819A1 (en) 2018-10-26 2021-06-03 Syndevrx Inc. Biomarkers of MetAP2 inhibitors and applications thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100117A (en) * 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto

Also Published As

Publication number Publication date
EP0418233A1 (fr) 1991-03-27
AU604944B2 (en) 1991-01-03
SE8702550D0 (sv) 1987-06-18
JPH02503917A (ja) 1990-11-15
WO1988010266A1 (fr) 1988-12-29
AU1960488A (en) 1989-01-19
US5037957A (en) 1991-08-06

Similar Documents

Publication Publication Date Title
DE3880632D1 (de) Kuevette.
DE3881291D1 (de) Sehapparat.
DE3862564D1 (de) Erdanker.
DE3867976D1 (de) Polymergebundene antioxydationsmittel.
DE3883705D1 (de) Alkenylbicyclohexane.
DE3876873D1 (de) Weblitzenuebergabevorrichtung.
FI873619A0 (fi) Rf-skyddad hybridkrets.
FI896029A0 (fi) Cysteinproteinas-inhibitor.
DE3785663D1 (de) Loetgeraet.
DE3876304D1 (de) Polysilacylobutasilazane.
DE3882446D1 (de) Polydisilacyclobutasilazane.
FI881655A0 (fi) Tvaettmedelssammansaettning.
DE3870513D1 (de) Tennisball.
NO882749D0 (no) Dental-sonde.
DE3888991D1 (de) Aminokohlenwasserstoff-substituierte Ketoximosilane.
FI77055B (fi) Vaermegradient-inkubator.
DE3879348D1 (de) Fm-cw-radargeraet.
DE3877421D1 (de) Polyamidbenzazole.
DE3862309D1 (de) Aminomethyltetrahydrofurane.
DE3878970D1 (de) Praeparative chromatographiesaeule.
FI885706A (fi) Foerbaettrade loesgoerningsbelaeggningar.
DE3861694D1 (de) Cyclopropancarboxamide.
DE3860710D1 (de) Exklusiv-oder-schaltung.
DE3860307D1 (de) 2-aminomethyltetrahydrofurane.
FI885653A0 (fi) Lockbete foer insekter.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: GRUBB, ANDERS

Owner name: TROJNAR, JERZY

Owner name: ABRAHAMSON, MAGNUS